This research focuses on maximising the benefits of proven smoking cessation interventions to support people who smoke to quit, as part of the strategy to help New Zealand become smokefree by 2025. A large, community-based clinical trial is planned that draws on 15 years of smoking cessation research undertaken by the study team. Our research has shown that both cytisine (a plant-based medicine that partially blocks the effects of nicotine on the brain) and nicotine e-cigarettes are more effective than nicotine replacement therapy at helping people to quit smoking, and are more acceptable to users. New Zealand research has also shown that text-messages offering advice and support around quitting smoking are highly effective and acceptable. The trial will test whether using all three stop-smoking products at once (cytisine, nicotine e-cigarettes, and text messages) will help more New Zealanders to quit long-term, compared to single product use.